Press releases
- Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
- Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
- Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
- Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
- Edwards Lifesciences Reports Fourth Quarter Results
- Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
- Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 77.56 |
Average volume | -- |
---|---|
Shares outstanding | 601.93m |
Free float | 596.57m |
P/E (TTM) | 37.91 |
Market cap | 52.51bn USD |
EPS (TTM) | 2.30 USD |
Data delayed at least 20 minutes, as of Dec 30 1899.
More ▼